ValenciaNOVEMBER201922ND

21ST

Chair

Dr. Mariano ProvencioHospital Univ. Puerta de Hierro, Majadahonda (Madrid)

13th

on

www.gecp.org/lungcancer2019

09:00 - 10:00 SESSION I: NSCLC. EARLY STAGES CURRENT MANAGEMENT

Chairs: Dr. José Luis González-Larriba Hospital Clínico San Carlos, Madrid

Dr. Teresa Morán ICO Badalona. Hospital Univ. German Trias i Pujol, Barcelona

09:00-09:15 Current treatment approaches in early diseases Dr. Bartomeu Massutí Hospital General Univ. de Alicante

09:15-09:30 Comorbidities: assessment tools and effect on outcome Dr. Jose Miguel Sánchez Hospital Univ. de la Princesa, Madrid

09:30-09:45 Primary prevention in Europe Prof. Enrica Capelletto University of Turin, Orbassano (Italy)

09:45-10:00 Discussion

10:00 - 11:00 MOLECULAR BOARD IN THE CLINICAL PRACTICE: SEPARATING FACTS FROM MYTHS

Chairs: Dr. Manuel Cobo Hospital Regional Univ. Carlos Haya, Málaga

Dr. Vanessa Ospina Hospital Univ. Fundación Santa Fe de Bogotá (Colombia)

10:00-10:15 Do you need it in your hospital? YES Dr. Manuel Cobo Hospital Regional Univ. Carlos Haya, Málaga

10:15-10:30 Do you need it in your hospital? NOT YET Dr. Jordi Remón Centro Integral Oncológico Clara Campal, Barcelona

10:30-10:45 Moving genomics to daily practice Dr. Bartomeu Massuti Hospital General Univ. de Alicante

10:45-11:00 Discussion

11:00-11:30 Coffee Break

Dr. Mariano ProvencioHospital Universitario Puerta de Hierro, Majadahonda, Madrid

Dr. Carlos CampsHospital General Univ. de Valencia

Dr. Bartomeu MassutíHospital General Univ. de Alicante

Dr. Alfredo SánchezHospital Provincial de Castellón

Dr. Ana BlascoHospital General. Univ. de Valencia

Dr. Oscar Juan-VidalHospital Univ. La Fe, Valencia

Dr. Natividad MartinezHospital General Univ. de Alicante

Dr. Amelia InsaHospital Clínico Univ. de Valencia

Dr. Maria GuiradoHospital General Univ. de Elche, Alicante

Dr. Mariano ProvencioHospital Universitario Puerta de Hierro, Majadahonda, Madrid

Dr. Carlos CampsHospital General Universitario, Valencia CIBERONC

Dr. Enric CarcerenyICO, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona

Dr. Bartomeu MassutíHospital General Universitario, Alicante

Dr. Ernest NadalICO, Hospital Durán i Reynals, L´Hospitalet de Llobregat, Barcelona

Dr. Manuel CoboHospital General Universitario Carlos Haya, Málaga

Dr. Ramón de las PeñasConsorcio Hospital Provincial, Castellón

Dr. Manuel DomineHopital Universitario Fundación Jiménez Díaz, Madrid

Dra. María Rosario García-CampeloHospital Teresa Herrera, A Coruña

Dr. Jose Luis Gonzalez LarribaHospital Clínico San Carlos, Madrid

Dra. Noemí ReguartHospital Clinic, Barcelona

Dra. Ivana Gabriela SullivanHospital Sant Pau, Barcelona

SCIENTIFIC COMMITEE

ORGANIZING COMMITEE

Thursday NOVEMBER201921ST

Thursday NOVEMBER201921ST

15:00 - 16:30 EDUCATIONAL SESSION: ADVANCES IN THE SURGICAL MANAGEMENT OF NSCLC

Chairs: Dr. Florentino Hernando-Trancho Hospital Clínico San Carlos, Madrid

Dr. Néstor Martínez Hospital de La Ribera, Alcira, Valencia

15:00-15:20 Lymphadenectomy and its implications. The SCAT trial Dr. José Ramón Jarabo Hospital Clínico San Carlos, Madrid

15:20-15:40 Lung cancer: SECT Multicenter working groups surgical results Dr. Sergi Call Hospital Univ. Mutua Terrassa, Barcelona

15:40-16:00 Quality criteria for the resection of thymic tumors and its registration Dr. Juan Carlos Trujillo Hospital Univ. de la Santa Creu i Sant Pau, Barcelona

16:00-16:30 Discussion

16:30 - 17:30 SESSION III: BIOLOGICAL PHENOMENA THAT INFLUENCES THE RESULTS

Chairs: Dr. Ivana Sullivan Hospital Univ. de la Santa Creu i Sant Pau, Barcelona

Dr. Luis Paz-Ares Hospital Univ. 12 de Octubre, Madrid

16:30-16:45 Heterogeneity, clonality and subclonality Dr. Nicholas McGranahan University College of London (UK)

16:45-17:00 NeoAntigenicity Dr. Rafael Sirera Universidad Politécnica de Valencia

17:00-17:15 Tumorstemcells.Keysinitsidentificationandtreatment Dr. Martin Barr Trinity College, Dublín (Ireland)

17:15-17:30 Discussion

17:30-18:00 Coffee Break

11:30 - 13:00 SESSION II: BIOLOGICAL FUNDAMENTALS FROM BASICS TO CLINICS

Chairs: Dr. Eloisa Jantus Hospital General Univ. de Valencia

Dr. Miguel A. Molina Hospital Univ. Quirón Dexeus, Barcelona

Dr. Atocha Romero Hospital Univ. Puerta de Hierro, Majadahonda, Madrid

11:30-11:45 Epigenetic biomarkers for cancer diagnosis Dr. Juan Sandoval Instituo de Investigación Sanitaria La Fe, Valencia

11:45-12:00 Early onset lung cancer Dr. Ernest Nadal ICO Hospitalet. Hospital Duran i Reynals, Barcelona

12:00-12:15 Emerging biomarkers in immune-oncology: Some insights from NADIM trial Dr. Alberto Cruz Hospital Univ. Puerta de Hierro, Majadahonda, Madrid

12:15-12:30 Liquid Biopsy: When sensitivity matters. Results from the RING study Dr. Atocha Romero Hospital Univ. Puerta de Hierro, Majadahonda, Madrid

12:30-12:45 New resistance mechanisms to EGFR-TKIs in NSCLC Dr. Jordi Bertran-Alamillo Hospital Univ. Quirón Dexeus, Barcelona

12:45-13:00 Discussion

13:00 - 13:30 CONFERENCE

Chair: Dr. Mariano Provencio Hospital Univ. Puerta de Hierro, Majadahonda, Madrid

DDR mechanisms and immunotherapy resistance Dr. Rafael Rosell Instituto de Investigación en Ciencias de la Salud Germans Trias i Pujol (IGTP) Badalona, Barcelona

13:30 - 15:00 SATELLITE LUNCH SYMPOSIUM Unique patients, unique approaches Sponsored by Roche

Terra meeting room (-1 floor)

18:00 - 18:45 SESSION IV: SUMMARY OF THE SLCG PROJECTS

Chairs: Dr. Alfredo Sánchez Hospital Provincial de Castellón

Dr. Joaquín Casal Complejo Hospitalario Univ. de Vigo

18:00-18:15 Earlystagesandfirstline: LINC/BR.31; NADIM; PEBEL, Atezo-BRAIN, TELMA, CHESS Dr. Ana Blasco Hospital General. Univ. de Valencia

18:15-18:30 Second line: DURVAST, BOOSTER, ALERT, REPLAY, THOMAS Dr. Joaquim Bosch ICOGirona.HospitalUniv. Dr.JosepTrueta,Girona

18:30-18:45 Other tumors and pharmacogenomic studies: STIMULI, Beat-MESO, Biopsia líquida, RING, SELINA Dr. Rafael López Hospital Clínico Univ. de Valladolid

18:45 - 19:30 SESSION V: OPTIMIZING TREATMENT IN STAGE III

Chairs: Dr. Amelia Insa Hospital Clínico Univ. de Valencia

Dr. Ana Laura Ortega Complejo Hospitalario de Jaén

18:45-19:00 Clinical-therapeuticsignificanceofthedifferent subtypes of stage III Dr. Maria Guirado Hospital General Univ. de Elche, Alicante

19:00-19:15 Integrating IO in treatment strategies Dr. Virginia Calvo Hospital Univ. Puerta de Hierro, Majadahonda, Madrid

19:15-19:30 Discussion

Friday NOVEMBER201922nd

08:00 - 09:00 PLENARY SESSION OF THE SLCG

09:00 - 10:00 SESSION VI: IMMUNE-CHECKPOINT INHIBITORS IN NSCLS: AS SINGLE AGENTS OR IN COMBINATION WITH CHEMOTHERAPY

Chairs: Dr. Antonio Araújo Centro Hospitalar do Porto (Portugal)

Dr. Remei Blanco Hospital de Terrassa, Barcelona

09:00-09:15 First line options for patients without oncogene driver Dr. Juan Coves Hospital Son Llàtzer, Palma de Mallorca

09:15-09:30 Rationale for combining treatments Dr. Ramón Palmero ICO Hospitalet. Hospital Duran i Reynals, Barcelona

09:30-09:45 Recommendations in the second line treatment using firstlinePDL1andTMBasapredictivebiomarker for immune-oncology therapy: Is there anything missing? Dr. Isidoro Barneto Hospital Univ. Reina Sofía, Córdoba

09:45-10:00 Discussion

10:00 - 11:00 PROFFERED PAPER SESSION

Chairs: Dr. Oscar Juan-Vidal Hospital Univ. La Fe, Valencia

Dr. María González Cao Hospital Univ. Dexeus, Barcelona

POSTER PRESENTATIONS & AWARDS Sponsored by Roche

Poster 18 Anti-egf antibodies increase the effect of alk and mek inhibitors in alk and kras nsclc cell lines

Poster 28 Osimertinib vs comparator egfr-tki as first-line treatment for egfrm advanced nsclc (flaura): final overall survival analysis

Poster 34 Functional systemic cd4 immunity is required for clinical responses to pd-l1/pd-1 blockade therapy in lung cancer

Poster 37 Lung tumorspheres reveal cancer stem cell properties, potential targets and a prognostic score for non-small cell lung cancer

Poster 49 Niveles basales de células supresoras mieloides inmaduras circulantes como marcadores predictivos de eficacia a inmunoterapia anti-pd1/pd-l1 en cáncer de pulmón no microcítico avanzado

Poster 50 A 770 gene panel expression analysis to predict clinical benefit of durvalumab in hiv-infected cancer patients

Friday NOVEMBER201922nd

13:30 - 14:15 SESSION IX: BIOLOGICAL CONCEPTS SURROUNDING RESISTANCE IN THE TREATMENT OF LUNG CANCER

Chairs: Dr. Reyes Bernabé Hospital Univ. Virgen del Rocío, Sevilla

Dr. Javier de Castro Hospital Univ. La Paz, Madrid

13:30-13:45 Biological basis of resistance mechanisms in oncogenic drivers Dr. Natividad Martínez Hospital General Univ. de Alicante

13:45-14:00 Biological basis resistance mechanisms in immunotherapy Dr. Santiago Viteri Hospital Univ. Quirón Dexeus, Barcelona

14:00-14:15 Discussion

14:15 - 15:15 SESSION X: SCLC NEW OPPORTUNITIES

Chair: Dr. Claudio Martín Instituto Alexander Fleming, Buenos Aires, Argentina

Dr. Manuel Dómine Hospital Univ. Fundación Jiménez Díaz, Madrid

14:15-14:30 Genomics of SCLC: Relevant advances Dr. Noemi Reguart Hospital Clinic de Barcelona

14:30-14:45 Immunotherapy in SCLC Dr. Antonio Calles Hospital General Univ. Gregorio Marañón, Madrid

14:45-15:00 New drugs Dr. Dolores Isla Hospital Clínico Univ. Lozano Blesa, Zaragoza

15:00-15:15 Discussion

15:15-15:20 Closing remarks

11:00 - 11:45 SESSION VII: REAL WORLD DATA IN LUNG CANCER

Chair: Dr. Carlos Carracedo ALIADAS, Instituto Nacional de Enfermedades Neoplásicas, Lima (Perú)

Dr. Sergio Vázquez Hospital Univ. Lucus Augusti, Lugo

11:00-11:15 The role of the SLCG tumors registry Dr. Mariano Provencio Hospital Univ. Puerta de Hierro, Majadahonda, Madrid

11:15-11:30 Implementing personalized care. The french experience Dr. Benjamin Besse Institut Gustave Roussy, Villejuif (France)

11:30-11:45 Discussion

11:45-12:30 Coffee Break

12:30 - 13:30 SESSION VIII: NSCLC STAGE IV TREATMENT IN ONCOGENIC ADDICTED DISEASE

Chairs: Dr. Carlos Camps Hospital General Univ. de Valencia

Dr. Mª Angeles Sala Hospital de Basurto, Bilbao

12:30-12:45 Treatment algorithms for EGFR mutated patients Dr. Rosario García-Campelo Hospital Univ. de A coruña

12:45-13:00 How to organize the treatment in ALK /ROS1+ patients Dr. Enric Carcereny ICO Badalona. Hospital Univ. Germans Trias i Pujol, Barcelona

13:00-13:15 Targeted therapy beyond EGFR-ALK-ROS1 Dr. Margarita Majem Hospital Univ. de la Santa Creu I Sant Pau, Barcelona

13:15-13:30 Discussion

Round table: Redefining survival expectation for patients in 1st line mNSCLC wildtype

Terra meeting room (-1 floor)

Sponsored by MSD

Platinum

Silver

Bronze

Other Collaborations

Supporting Companies

This activity has been recognized as of scientific interest by the Health and Social Services Ministry.

Activitat acreditada pel Consell Català de la Formació Continuada de les Professions Sanitàries (CCFCPS) - Comisión de Formación Continuada del Sistema Nacional de Salud con 1,5 CRÉDITOS, expedient núm.: 09/025931-MD.

It is mandatory to attend the 100% of the congress plenary sessions to obtain the certificate of attendance with credits. Please do not forget to scan your badge at the entrance of the meeting room everyday.

General Information

Under the Auspices of

Credits

ScientificInterest

Venue

Hotel Meliá ValenciaAv. de Les Corts Valencianes 5246015 Valencia

Holding a badge will be required to access the meeting room.

Conference Secretariat

Language

Lectures will be delivered in English or Spanish.

Monasterios de Suso y Yuso 34 · 28049 Madrid (+34) 91 372 02 03 e-mail: lungcancer2019@doctaforum.comwww.gecp.org/lungcancer2019